Suprachoroidal Administration in Subjects With Metastases to the Choroid

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 16, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

February 28, 2027

Conditions
Eye CancerPrimary Cancer
Interventions
DRUG

AU-011

AU-011 Via Suprachoroidal Administration with laser treatment

DEVICE

SCS Microinjector

Suprachoroidal Injection Device

DEVICE

Laser

Laser Administration

Trial Locations (9)

19107

NOT_YET_RECRUITING

Shields and Shields, PC, Philadelphia

33136

NOT_YET_RECRUITING

Bascom Palmer Eye Institute, Miami

37203

RECRUITING

Tennessee Retina, PC, Nashville

44195

NOT_YET_RECRUITING

Cleveland Clinic, Cole Eye Institute, Cleveland

48105

RECRUITING

Kellogg Eye Center, Ann Arbor

77401

RECRUITING

Retina Consultants of Texas, Bellaire

94303

NOT_YET_RECRUITING

Byers Eye Institute at Stanford University, Palo Alto

98104

RECRUITING

University of Washington, Seattle

02114

RECRUITING

Massachusetts Eye and Ear, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Aura Biosciences

INDUSTRY

NCT06643884 - Suprachoroidal Administration in Subjects With Metastases to the Choroid | Biotech Hunter | Biotech Hunter